A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally Daily to Subjects With Solid Tumors.

Trial Profile

A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally Daily to Subjects With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2014

At a glance

  • Drugs XL 281 (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Sponsors Exelixis
  • Most Recent Events

    • 11 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 11 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 May 2010 Planned number of patients changed from 160 to 180 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top